239 related articles for article (PubMed ID: 23826928)
1. Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn's disease medications and hepatosplenic T-cell lymphoma.
Selvaraj SA; Chairez E; Wilson LM; Lazarev M; Bass EB; Hutfless S
Syst Rev; 2013 Jul; 2():53. PubMed ID: 23826928
[TBL] [Abstract][Full Text] [Related]
2. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review.
Ochenrider MG; Patterson DJ; Aboulafia DM
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):144-8. PubMed ID: 20371449
[TBL] [Abstract][Full Text] [Related]
3. Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System.
Shah ED; Coburn ES; Nayyar A; Lee KJ; Koliani-Pace JL; Siegel CA
Aliment Pharmacol Ther; 2020 Mar; 51(5):527-533. PubMed ID: 31990422
[TBL] [Abstract][Full Text] [Related]
4. Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk.
Parakkal D; Sifuentes H; Semer R; Ehrenpreis ED
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1150-6. PubMed ID: 21941193
[TBL] [Abstract][Full Text] [Related]
5. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
6. Hepatosplenic T-cell lymphoma in a 47-year-old Crohn's disease patient on thiopurine monotherapy.
van de Meeberg MM; Derikx LA; Sinnige HA; Nooijen P; Schipper DL; Nissen LH
World J Gastroenterol; 2016 Dec; 22(47):10465-10470. PubMed ID: 28058028
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.
Kotlyar DS; Osterman MT; Diamond RH; Porter D; Blonski WC; Wasik M; Sampat S; Mendizabal M; Lin MV; Lichtenstein GR
Clin Gastroenterol Hepatol; 2011 Jan; 9(1):36-41.e1. PubMed ID: 20888436
[TBL] [Abstract][Full Text] [Related]
8. Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease.
Drini M; Prichard PJ; Brown GJ; Macrae FA
Med J Aust; 2008 Oct; 189(8):464-5. PubMed ID: 18928444
[TBL] [Abstract][Full Text] [Related]
9. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.
Mackey AC; Green L; Liang LC; Dinndorf P; Avigan M
J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):265-7. PubMed ID: 17255842
[TBL] [Abstract][Full Text] [Related]
10. Hepatosplenic T-cell lymphoma and inflammatory bowel disease.
Thai A; Prindiville T
J Crohns Colitis; 2010 Nov; 4(5):511-22. PubMed ID: 21122554
[TBL] [Abstract][Full Text] [Related]
11. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?
Rosh JR; Gross T; Mamula P; Griffiths A; Hyams J
Inflamm Bowel Dis; 2007 Aug; 13(8):1024-30. PubMed ID: 17480018
[TBL] [Abstract][Full Text] [Related]
12. The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006.
Herrinton LJ; Liu L; Abramson O; Jaffe ES
Pharmacoepidemiol Drug Saf; 2012 Jan; 21(1):49-52. PubMed ID: 21823196
[TBL] [Abstract][Full Text] [Related]
13. Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infliximab therapy.
Zeidan A; Sham R; Shapiro J; Baratta A; Kouides P
Leuk Lymphoma; 2007 Jul; 48(7):1410-3. PubMed ID: 17613771
[No Abstract] [Full Text] [Related]
14. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
15. Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review.
Yabe M; Medeiros LJ; Daneshbod Y; Davanlou M; Bueso-Ramos CE; Moran EJ; Young KH; Miranda RN
Ann Diagn Pathol; 2017 Feb; 26():16-22. PubMed ID: 28038706
[TBL] [Abstract][Full Text] [Related]
16. Crohn's disease, hepatosplenic T-cell lymphoma and no biological therapy: are we barking up the wrong tree?
Moran G; Dillon J; Green J
Inflamm Bowel Dis; 2009 Sep; 15(9):1281-2. PubMed ID: 19067412
[No Abstract] [Full Text] [Related]
17. Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system.
Théophile H; Schaeverbeke T; Miremont-Salamé G; Abouelfath A; Kahn V; Haramburu F; Bégaud B
Drug Saf; 2011 Jul; 34(7):577-85. PubMed ID: 21663333
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.
Kip KE; Swoger JM; Grandinetti LM; Barrie AM; Greer JB; Regueiro MD
Inflamm Bowel Dis; 2013 May; 19(6):1164-72. PubMed ID: 23518804
[TBL] [Abstract][Full Text] [Related]
19. Hepatosplenic T-cell lymphoma (HSTCL) in patient with Crohn's disease treated with azathioprin.
Soria-López E; Casanova-Espinosa M; Fernández Pérez F
Med Clin (Barc); 2021 Jun; 156(11):579-580. PubMed ID: 32439154
[No Abstract] [Full Text] [Related]
20. Is there a benefit from the concomitant use of immunosupression with anti-TNF in Crohn's disease; heads or tails?
Lakatos PL
Rev Recent Clin Trials; 2009 Sep; 4(3):152-8. PubMed ID: 20028325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]